Related Experiment Video

Updated: Aug 15, 2026

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

Investigational agents that protect pancreatic islet beta-cells from failure

Kathryn Aston-Mourney1, Joseph Proietto, Sofianos Andrikopoulos

  • 1Department of Medicine (AH/NH), Heidelberg Repatriation Hospital, University of Melbourne, Heidelberg Heights, Victoria 3081, Australia.

Expert Opinion on Investigational Drugs
|September 28, 2005
PubMed

Insights

Type 2 diabetes treatments aim to protect pancreatic islet beta-cells, crucial for insulin secretion and managing hyperglycemia. Emerging therapies focus on preserving beta-cell function and mass to prevent diabetic complications.

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology
  • Cell Biology

Background:

  • Type 2 diabetes is characterized by insulin resistance and declining insulin secretion, leading to hyperglycemia and complications.
  • The deterioration of islet beta-cell function and survival is a key driver of hyperglycemia in Type 2 diabetes.
  • Maintaining normal beta-cell function and preventing cell death are critical therapeutic goals.

Purpose of the Study:

  • To review existing and emerging therapies for Type 2 diabetes with a focus on islet beta-cell protection.
  • To examine the potential islet-protective functions of current Type 2 diabetes medications.
  • To discuss future therapeutic strategies targeting beta-cell failure.

Main Methods:

  • Literature review of existing research on Type 2 diabetes therapies.
  • Analysis of evidence for the beta-cell protective effects of metformin and thiazolidinediones.
  • Evaluation of newer agents, including glucagon-like peptide-1 (GLP-1) based therapies.
  • Exploration of future drug targets such as advanced glycation end products (AGEs), oxidative stress, and endoplasmic reticulum (ER) stress.

Main Results:

  • Existing therapies like metformin and thiazolidinediones may possess islet-protective properties beyond glucose lowering or insulin sensitization.
  • Emerging GLP-1 based therapies demonstrate potential not only to stimulate insulin secretion but also to increase islet beta-cell mass.
  • Future drug development should consider targeting AGEs, oxidative stress, and ER stress to prevent beta-cell failure.

Conclusions:

  • Therapies for Type 2 diabetes should aim to preserve and protect pancreatic islet beta-cells.
  • Both existing and novel therapeutic approaches show promise in maintaining beta-cell function and mass.
  • Targeting pathways involved in beta-cell stress and damage represents a promising future direction for Type 2 diabetes management.

More Related Videos

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...